Original language | English |
---|---|
Pages (from-to) | 60-75 |
Number of pages | 16 |
Journal | Eurointervention |
Volume | 16 |
Issue number | 1 |
DOIs | |
Publication status | Published - 2020 |
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Eurointervention, Vol. 16, No. 1, 2020, p. 60-75.
Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - The SYNTAX score on its way out or … towards artificial intelligence: part II
AU - Serruys, Patrick W.
AU - Chichareon, Ply
AU - Modolo, Rodrigo
AU - Leaman, David M.
AU - Reiber, Johan H. C.
AU - Emanuelsson, H. kan
AU - di Mario, Carlo
AU - Pijls, Nico H. J.
AU - Morel, Marie-Angèle
AU - Valgimigli, Marco
AU - Farooq, Vasim
AU - van Klaveren, David
AU - Capodanno, Davide
AU - Andreini, Daniele
AU - Bourantas, Christos V.
AU - Davies, Justin
AU - Banning, Adrian P.
AU - Escaned, Javier
AU - Piek, Jan J.
AU - Echavarría-Pinto, Mauro
AU - Taylor, Charles Anthony
AU - Thomsen, Brian
AU - Collet, Carlos
AU - Pompilio, Giulio
AU - Bartorelli, Antonio L.
AU - Glocker, Ben
AU - Dressler, Ovidiu
AU - Stone, Gregg W.
AU - Onuma, Yoshinobu
N1 - Funding Information: P.W. Serruys reports personal fees from Abbott Laboratories, AstraZeneca, Biotronik, Cardialysis, GLG Research, Medtronic, Sino Medical Sciences Technology, Société Europa Digital & Publishing, Stentys France, Svelte Medical Systems, Philips/ Volcano, St. Jude Medical, Qualimed, and Xeltis, outside the submitted work. P. Chichareon reports a research grant from Biosensors outside the submitted work. R. Modolo has received research grants from Biosensors outside the submitted work and from the Sao Paulo Research Foundation (FAPESP – grant number 2017/22013-8). N. Pijls has received institutional research grants from Abbott, Hexacath and HeartFlow, is a consultant for Abbott, Opsens, and GE Healthcare, and possesses equity in Philips, HeartFlow, and ASML. M. Valgimigli reports grants and personal fees from Abbott, Terumo and AstraZeneca, personal fees from Chiesi, Bayer, Daiichi Sankyo, Amgen, Alvimedica, Idorsia, Biosensors, CoreFlow, Vifor and Bristol-Myers Squibb, and grants from Medicure, outside the submitted work. J. Davies reports grants, personal fees and other from Philips Volcano, outside the submitted work; in addition, J. Davies has a patent iFR with royalties paid by Philips Volcano to Imperial College London. A. Banning is partially supported by the NIHR Oxford Biomedical Research Centre and reports grants from Boston Scientific and personal fees from Boston Scientific, Medtronic and Abbott Vascular, during the conduct of the study. J.J. Piek reports non-financial support from Abbott Vascular and personal fees and non-financial support from Philips/Volcano, outside the submitted work. B. Thomsen is an employee of GE Healthcare. B. Glocker reports grants from HeartFlow, and the European Commission, during the conduct of the study, personal fees from Kheiron Medical Technologies, Definiens, Axon Advisors, and GlaxoSmithKline, grants from UKRI, EPSRC, Innovate UK, and MRC/NIHR, outside the submitted work. C. Collet reports grants and personal fees from HeartFlow Inc, and personal fees from Philips and Abbott Vascular, outside the submitted work. G.W. Stone reports personal fees from Terumo, Amaranth, Shockwave, Valfix, TherOx, Reva, Vascular Dynamics, Robocath, HeartFlow, Gore, Ablative Solutions, Matrizyme, Miracor, Neovasc, V-wave, Abiomed, Claret, Backbeat, Sirtex and MAIA Pharmaceuticals, personal fees and other from Ancora, Qool Therapeutics and SpectraWave, other from Cagent, Applied Therapeutics, Biostar family of funds, and MedFocus family of funds, outside the submitted work; Columbia University, his employer, receives royalties from Abbott for sales of the MitraClip. Y. Onuma reports being a member of the advisory board of Abbott Vascular. C. Taylor reports being a shareholder in and an employee of HeartFlow. The other authors have no conflicts of interest to declare. The Guest Editor is a consultant for Edwards Lifesciences.
PY - 2020
Y1 - 2020
UR - http://www.scopus.com/inward/record.url?scp=85085156947&partnerID=8YFLogxK
U2 - https://doi.org/10.4244/EIJ-D-19-00543B
DO - https://doi.org/10.4244/EIJ-D-19-00543B
M3 - Article
C2 - 31651398
SN - 1774-024X
VL - 16
SP - 60
EP - 75
JO - Eurointervention
JF - Eurointervention
IS - 1
ER -